Hsiao noted the options are adalimumab, a tumor necrosis factor α inhibitor; secukinumab, an IL-17A inhibitor; and ...
Trotter said dermatologists should pay attention to locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).
She described the patient consult as the starting point for aesthetic care. It covers the patient’s history, motivation for seeking treatment, prior aesthetic procedures, keloid history, and herpes ...